

Exploring the Link Between *Helicobacter pylori* Infection and Cardiovascular Disease Risk: Clinical Implications and Future Research

Akash Patel MD^{1*}, Utsav Vaghani MD², Sarang Tusharbhai Mehta MD³

¹Department of Internal Medicine, Eisenhower Medical Centre, Rancho Mirage, California, USA

²Department of Internal Medicine, UNM Children Hospital, Surat, Gujarat, India

³Department of Internal Medicine, Smt. N.H.L. Municipal Medical College, Ahmedabad, Gujarat, India

Citation: Akash Patel MD, Utsav Vaghani MD, Sarang Tusharbhai Mehta. Exploring the Link Between *Helicobacter pylori* Infection and Cardiovascular Disease Risk: Clinical Implications and Future Research. *Int Jour Gastro Hepat.* 2023;2(2):1-4.

Received Date: 07 November, 2023; **Accepted Date:** 10 November, 2023; **Published Date:** 11 November, 2023

***Corresponding author:** Akash Patel MD, Wellstar Kennestone Regional Hospital, USA

Copyright: © Akash Patel MD, Open Access 2023. This article, published in *Int Jour Gastro Hepat (IJGH)* (Attribution 4.0 International), as described by <http://creativecommons.org/licenses/by/4.0/>.

ABSTRACT

Helicobacter pylori (*H. pylori*) infection is associated with an increased risk of cardiovascular diseases (CVD), with variable prevalence rates worldwide. The pathogen contributes to CVD through mechanisms such as inflammation, lipid metabolism dysregulation, and enhanced platelet aggregation, which are linked to atherosclerosis development. Treatment typically involves antibiotics and proton pump inhibitors, and may confer additional cardiovascular benefits by addressing the bacterium's systemic effects. Future research should focus on the long-term impact of *H. pylori* eradication on CVD risk and outcomes, potentially informing prevention strategies. This review underscores the necessity for a comprehensive understanding of *H. pylori*'s implications for cardiovascular health.

INTRODUCTION

Helicobacter pylori (*H. pylori*), a Gram-negative bacterium, has garnered global attention due to its widespread prevalence and role in various diseases. In China, over 44% of the population is affected,^[1] and the prevalence peaks at 53.3% among individuals aged 13 and older in Saudi Arabia.^[2] The United States has lower prevalence of 35.6%, with a noteworthy decrease in infection rates with advancing age and significant racial disparities.^[3, 4] The relationship between *H. pylori* and cardiovascular disease (CVD) is particularly compelling, with evidence suggesting that the bacterium could contribute to the risk and progression of atherosclerosis, myocardial infarction, and cerebrovascular disease.^[5-7]

Cardiovascular Pathogenesis Tied to *H. pylori* Infection:

H. pylori's influence on cardiovascular health is mediated through several pathways including chronic inflammation, dysregulation of lipid metabolism, and prothrombotic tendencies.^[8-11] These mechanisms

necessitate an integrated approach to treatment that addresses both the infection and its cardiovascular implications.^[12-15]

H. pylori's involvement in CVD is multifaceted, disturbing lipid profiles, and fostering systemic inflammation and hypercoagulability.^[5,6] The bacterium is correlated with increased LDL and decreased HDL cholesterol levels, potentiating atherosclerosis. Inflammatory markers such as IL-6 and TNF- α are also elevated, promoting atherosclerotic plaque instability and thrombosis. Moreover, *H. pylori* infection heightens platelet aggregation, contributing to cardiovascular incidents.^[6]

Moreover, the infection's induction of endothelial dysfunction signifies its role in the progression of atherosclerosis,^[9] while dyslipidemia induced by the bacterium further augments cardiovascular risk.^[5,16] The organism's effect on coagulation and reactive oxygen species formation intensifies its role in CVD,^[9,10] thereby positioning *H. pylori* as a significant factor in cardiovascular pathology.^[11]

Implications of *H. pylori* Treatment on Cardiovascular Risk:

Current treatment guidelines emphasize a combination therapy involving antibiotics and proton pump inhibitors, aiming for successful bacterial eradication.^[12-14] The indirect effects of treating *H. pylori*, such as the prevention of peptic ulcer complications, may also lessen cardiovascular risk.^[17] This potential to diminish atherosclerotic events and enhance dyslipidemia management positions *H. pylori* treatment as a pivotal component of CVD risk reduction.^[6,18]

Future Research Directions:

The intriguing association between *H. pylori* eradication and reduced cardiovascular morbidity warrants further investigation. Future research should aim to clarify the mechanisms by which *H. pylori* contributes to CVD and establish more concrete evidence for its role in cardiovascular outcomes. Longitudinal studies evaluating the impact of *H. pylori* treatment on cardiovascular disease incidence and mortality would be particularly valuable. Additionally, clinical trials focused on the cardiovascular benefits of *H. pylori* eradication could illuminate the potential for this treatment as a preventive measure in at-risk populations.

CONCLUSION

In conclusion, while the link between *H. pylori* and cardiovascular diseases is increasingly substantiated, the pathogenic pathways and clinical implications continue to be an area of dynamic research. It remains crucial for the medical community to consider the implications of *H. pylori* infection not only on gastrointestinal health but also on cardiovascular disease risk and progression. With continued exploration, the prospect of *H. pylori* treatment as a strategy for cardiovascular disease prevention may transition from hypothesis to practice.

REFERENCES

1. Shuai Ren, Pengpeng Cai, Yaqian Liu, Tianpei Wang, Yan Zhang, Qian Li, et al. Prevalence of Helicobacter Pylori Infection in China: A Systematic Review and Meta-analysis. J Gastroenterol Hepatol . 2022;37(3):464-470.
2. Mohammed Akeel, Erwa Elmakki, Atef Shehata, Ahmed Elhafey, Thanaa Aboshouk, Hussein Ageely, et al. Prevalence and Factors Associated With H. Pylori Infection in Saudi Patients With Dyspepsia. Electron Physician. 2018;10(9):7279-86.
3. Matthew G Varga, Julia Butt, William J Blot, Loïc Le Marchand, Christopher A Haiman, Yu Chen, et al. Racial Differences in Helicobacter Pylori CagA Sero-Prevalence in a Consortium of Adult Cohorts in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(10):2084-2092.
4. Hoda M. Malaty, Jong G. Kim, Soon D. Kim, and David Y. Graham. Prevalence of Helicobacter Pylori Infection in Korean Children: Inverse Relation to Socioeconomic Status Despite a Uniformly High Prevalence in Adults. American Journal of Epidemiology, 1996;143:3.
5. Su Youn Nam, Kum Hei Ryu, Bum Joon Park, Sohee Park. Effects of Helicobacter Pylori Infection and Its Eradication on Lipid Profiles and Cardiovascular Diseases. Helicobacter. 2015;20(2):125-32.
6. Bin Wang, Mingyang Yu, Rongguang Zhang, Shuaiyin Chen, Yuanlin Xi, Guangcai Duan. A Meta-analysis of the Association Between Helicobacter Pylori Infection and Risk of Atherosclerotic Cardiovascular Disease. Helicobacter. 2020;25(6):e12761.
7. Mitsushige Sugimoto, Kyoko Sakai, Masakazu Kita, Jiro Imanishi, Yoshio Yamaoka. Prevalence of Helicobacter Pylori Infection in Long-Term Hemodialysis Patients. Kidney Int. 2009;75(1):96-103.
8. Antonietta Gerarda Gravina, Rocco Maurizio Zagari, Cristiana De Musis, Lorenzo Romano, Carmelina Loguercio, Marco Romano. Helicobacter Pylori and Extragastric Diseases: A Review. World J Gastroenterol . 2018;24(29):3204-3221.
9. Xia, X., et al., Helicobacter Pylori Infection and Endothelial Dysfunction. 2021.
10. Paul A Corcoran, John C Atherton, Steve W Kerrigan, Torkel Wadstrom, Frank E Murray, Richard M Peek, et al., The Effect of Different Strains Of Helicobacter Pylori on Platelet Aggregation. Can J Gastroenterol. 2007;21(6):367–370.
11. Sarah Wernly, Georg Semmler, Andreas Völkerer, Maria Flamm, Elmar Aigner, David Niederseer, et al. Helicobacter Pylori and Cardiovascular Risk: Only a Dead Helicobacter Is a Good Helicobacter?. Helicobacter . 2022;27(6):e12928.
12. Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, et al., Evidence-Based Guidelines for the Treatment of Helicobacter Pylori Infection in Korea 2020. Gut Liver . 2021;15(2):168-195.
13. Michal Kori, Ilva Daugule, Vaidotas Urbonas. Helicobacter Pylori and Some Aspects of Gut Microbiota in Children. Helicobacter. 2018;23 Suppl 1:e12524.
14. Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu. Quinolone-Containing Therapies in the Eradication Of Helicobacter Pylori. Biomed Res Int. 2014;2014:151543.
15. Wasef Na'amnih, Amir Ben Tov, Amna Bdaire-Amsaha, Shlomi Cohen, Judith Tsamir, Gabriel Chodick, et al. Physicians' Adherence to Management Guidelines for H. Pylori Infection and Gastroesophageal Reflux Disease: A Cross-Sectional Study. Isr J Health Policy Res. 2020;9(1):28.

16. Mukhtar MH, WA Nasif, AT. Babakr. Helicobacter Pylori Infection Is Associated With Dyslipidemia and Increased Levels of Oxidized LDL in Type-2 Diabetes Mellitus. Journal of Diabetes Mellitus, 2016;6:3.
17. D Manuel, A Cutler, J Goldstein, M B Fennerty, K Brown. Decreasing Prevalence Combined With Increasing Eradication of Helicobacter Pylori Infection in the United States Has Not Resulted in Fewer Hospital Admissions for Peptic Ulcer Disease-Related Complications. Aliment Pharmacol Ther. 2007;25(12):1423-7.
18. Young-Il Kim, Young Ae Kim, Jang Won Lee, Hak Jin Kim, Su-Hyun Kim, Sang Gyun Kim, et al., Effect of Helicobacter Pylori Treatment on Long-Term Mortality in Patients With Hypertension. Gut Liver. 2020;14(1):47–56.